Treatment Action Group, New York, New York 10012, USA.
Clin Infect Dis. 2010 May 15;50 Suppl 3:S260-6. doi: 10.1086/651500.
Tuberculosis (TB) and human immunodeficiency virus (HIV) infections are the deadliest chronic infections globally. Although each is deadly alone, they are deadlier together, with TB causing one-quarter of AIDS-related deaths and HIV infecting at least 15% of patients with TB worldwide. Historically, the 2 diseases were treated through specific, vertical programs. Strong activism and massive scientific investment have boosted the global response to AIDS, whereas TB has suffered from weak advocacy and anemic research funding. However, since 2004, there has been increasing collaboration and convergence between programs to control the 2 diseases, driven by the recognition that program cooperation leads to synergistic gains in strengthening responses to the 2 diseases and to health systems in general. Progress to date is incomplete, however, and countries must rededicate themselves to scaling up prevention and treatment programs for TB and HIV infection toward universal access, while pursuing accelerated research efforts to develop effective vaccines, better treatments, and cures for both diseases.
结核病(TB)和人类免疫缺陷病毒(HIV)感染是全球最致命的慢性传染病。尽管每种疾病单独存在时就已经很致命,但它们在一起时更加致命,结核病导致四分之一的艾滋病相关死亡,而 HIV 感染了全球至少 15%的结核病患者。历史上,这两种疾病是通过专门的垂直项目进行治疗的。强有力的行动主义和大量的科学投资推动了全球对艾滋病的应对,而结核病则因宣传不力和研究资金不足而受到影响。然而,自 2004 年以来,控制这两种疾病的项目之间的合作和趋同不断增加,这是因为人们认识到,项目合作可以在加强对这两种疾病的应对以及整个卫生系统方面带来协同增益。然而,迄今为止进展并不完整,各国必须再次致力于扩大结核病和 HIV 感染的预防和治疗方案,以实现普及,同时加快研究努力,开发针对这两种疾病的有效疫苗、更好的治疗方法和治愈方法。